Objective To evaluate the efficacy and safety of first-line third-generation EGFR-tyrosine kinase inhibitor (EGFR-TKI) combined with pemetrexed-platinum chemotherapy in patients with EGFR-mutant advanced lung adenocarcinoma and brain parenchymal metastases. Methods A bicenter retrospective cohort study was conducted. A...
Jian-Xi Zhou, Ying-Hao Wang, Kang Wen et al.· Frontiers in Pharmacology· 0 citations
Objective To evaluate the efficacy and safety of ivonescimab plus chemotherapy versus bevacizumab plus chemotherapy in advanced EGFR-mutant lung adenocarcinoma after EGFR-TKI failure, and provide the first real-world head-to-head comparative evidence. Methods This two-center retrospective propensity score-matched (PSM)...
Jian-Xi Zhou, Ying-Hao Wang, Kang Wen et al.· Drug Design, Development and...· 0 citations
Stimulator of interferon genes (STING) agonists have shown limited antitumor efficacy, in part because STING activation is not preferentially focused on dendritic cells (DCs), which specialize in cross-priming. We present a DC-centric strategy that synergistically licenses DCs by coordinating CD47-SIRPα checkpoint reli...
An XPO1-TRIM21-TNFSF15 axis is defined that promotes the polarization of immunosuppressive TREM2+ macrophages, which ultimately orchestrates immune exclusion by impairing antigen presentation and enhances the efficacy of anti-PD1 immunotherapy in mice.
Qing-Wu Du, Ting-Ting Qin, Jing-Ya Wang et al.· Nature Communications· 0 citations
